ING Groep NV Invests $3.24 Million in Repligen Corporation $RGEN

ING Groep NV acquired a new stake in Repligen Corporation (NASDAQ:RGEN) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 19,800 shares of the biotechnology company’s stock, valued at approximately $3,244,000.

Other hedge funds also recently made changes to their positions in the company. Bayforest Capital Ltd acquired a new position in shares of Repligen in the 4th quarter valued at $32,000. Rachor Investment Advisory Services LLC acquired a new position in shares of Repligen in the 4th quarter valued at $33,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Repligen in the 3rd quarter valued at $29,000. Los Angeles Capital Management LLC acquired a new position in shares of Repligen in the 4th quarter valued at $36,000. Finally, Farther Finance Advisors LLC raised its stake in shares of Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

Repligen stock opened at $125.33 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The company has a market capitalization of $7.07 billion, a PE ratio of 139.26, a price-to-earnings-growth ratio of 2.36 and a beta of 1.09. Repligen Corporation has a one year low of $100.99 and a one year high of $175.77. The business has a 50 day simple moving average of $118.88 and a 200 day simple moving average of $138.50.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.38 by $0.10. The business had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.Repligen’s revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the company earned $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, sell-side analysts forecast that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on RGEN. JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 7th. Roth Mkm started coverage on Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 target price for the company. Wolfe Research started coverage on Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Finally, HSBC cut their target price on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $164.64.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.